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Objective: Breast cancer is the most common cancer among women worldwide. The Nordic 
countries have relatively high survival, but Denmark has a lower survival than neighboring 
countries. A breast cancer screening program was introduced in 2007 and 2008 in the northern 
and central regions of Denmark respectively. We aimed to examine possible changes in survival 
of Danish breast cancer patients in central and northern Denmark in the period 1998–2009.
Materials and methods: From the northern and central Denmark regions, we included all 
women (n = 13,756) with an incident diagnosis of breast cancer, as recorded in the Danish 
National Registry of Patients during the period January 1, 1998 through December 31, 2009. 
We calculated age-stratified survival and used Cox proportional hazard regression to estimate 
mortality rate ratios (MRRs) for all breast cancer patients.
Results: Median age was 62 years (21–102 years). The overall 1-year survival improved steadily 
over the period from 90.9% in 1998–2000 to 94.4% in 2007–2009, corresponding to a 1-year 
age adjusted MRR of 0.68 in 2007–2009 compared with the reference period 1998–2000. We 
estimated the 5-year survival to improve from 70.0% in 1998–2000 to 74.7% in 2007–2009, 
corresponding to a 5-year age adjusted MRR of 0.82 in 2007–2009 compared with the refer-
ence period 1998–2000. For middle-aged women (50–74 years) 1-year survival increased from 
92.8% in 1998–2000 to 96.6% in 2008–2009, and 5-year survival was expected to increase 
from 73.9% in 1998–2000 to 80.2% in 2007–2009. Among younger women (15–49 years) and 
elderly women (.75 years), 1-year survival and 5-year predicted survival did not change over 
the two time periods.
Conclusion: Survival of breast cancer patients has improved in Denmark over the period 
1998–2009, and this change was most distinct in women aged 50–74 years. Survival improved 
even before the implementation of a formal breast cancer screening program.
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Introduction
Breast cancer accounts for a substantial proportion of the cancer burden in women, 
with an estimated 1.4 million new cases per year and more than 450,000 breast 
cancer-related deaths per year worldwide.1 In Denmark, breast cancer accounted for 
29% of all incident cancers and 16% of all cancer deaths among women in the period 
1999–2003.1
Despite increasing survival in the Nordic countries, Denmark still has a deficit com-
pared with the other Nordic countries. In 2005–2007, Denmark had a 3.0% lower 1-year 
and 6.1% lower 5-year survival than Sweden.2–4 Prompted by the general lower cancer 
survival in Denmark compared with neighboring countries, National Cancer Plans5 Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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were introduced in 2002 and 2005, respectively, aiming to 
improve survival of cancer patients.6
Breast cancer treatment in Denmark is standardized in 
programs formed by the Danish Breast Cancer Coopera-
tive Group (DBCG). These programs have changed over 
the last decade towards a more widespread use of sentinel 
node technique and breast conserving surgery with adjuvant 
radiotherapy,7 prolonged use of tamoxifen, and introduction 
of aromatase inhibitors.8 Use of chemotherapy has improved 
with anthracyclines and/or taxanes, and most recently, 
in 2006, anti-HER2-therapy with trastuzumab according to 
the biomarker profile has been added to the programs.8,9 The 
beneficial effect of these treatments on survival has been 
documented in randomized controlled trials,10,11 and data 
from the DBCG database have, during the period 1977–2006, 
shown an increase in 5-year survival in Danish breast cancer 
patients from 65% to 81%.12
A breast cancer mammographic screening program was 
introduced in 2007 and 2008 in the northern and central 
regions of Denmark, respectively and may influence survival. 
Numerous investigations have proven a 25%–30% increased 
survival after introduction of screening programs in other 
countries.13–15
We used population-based registries in northern and 
central Denmark to examine changes in the mortality and 
survival of breast cancer patients of all ages between 1998 
and 2009.
Material and methods
We conducted this study in the central and the northern 
  Denmark regions, with a total population of 1.8   million 
persons. The National Health Service provides tax-supported 
health care for all inhabitants of Denmark, guaranteeing 
free treatment in hospitals. Virtually no breast cancer 
patients were treated in private hospitals during the study 
period.16
Identification of breast cancer patients
Through the Danish National Registry of Patients (DNRP), 
we identified all women resident in the northern or central 
regions of Denmark who had their first breast cancer diag-
nosis recorded in a hospital within one of the two regions 
over the period January 1, 1998 through December 31, 2009. 
The DNRP contains information about all admissions from 
nonpsychiatric hospitals in Denmark since 1977 and outpa-
tient data from 1995.17 This registry includes information on 
civil registration number, dates of admission and discharge, 
surgical procedure(s) performed, and up to 20 diagnoses 
from each hospital contact. Since 1994, diagnoses have 
been classified according to the International Classification 
of Diseases 10th edition (ICD-10). The ICD codes used to 
identify breast cancer were ICD-10 C50.x.
Survival
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit personal identification num-
ber to all Danish citizens.18 This number, unique to each 
Danish resident, is used in all Danish registries, allowing 
unambiguous individual-level data linkage. From the Civil 
Registration System we also obtained information on vital 
status (dead or alive), date of death, and residence for 
all cancer patients.
Statistical analysis
We followed each patient from date of cancer diagnosis 
until emigration, death, or June 25, 2010, whichever came 
first. To visualize crude survival we constructed Kaplan–
Meier curves, stratified according to period of diagnosis 
(1998–2000, 2001–2003, 2004–2006, and 2007–2009). We 
estimated 1-, 3-, and 5-year survival. In the latter periods we 
estimated 3- and 5-year survival using a hybrid analysis in 
which we included the actual survival for as long as possible 
and then estimated the conditional probability of surviving 
thereafter based on the corresponding survival experi-
ence of patients in the previous period (ie, using a period 
analysis technique).19 To compare all-cause mortality over 
time, we used Cox proportional hazard regression analysis, 
with 1998–2000 as the reference period to estimate 1-, 3-, 
and 5-year mortality rate ratios (MRRs) and corresponding 
95% confidence intervals (CIs), adjusting for age group 
(15–49 years, 50–74 years, and .75 years).
Analyses were performed using SAS (v 9.2; SAS 
  Institute, Inc, Cary, NC).
Results
A total of 13,756 women had incident breast cancer during 
the period 1998–2009, with a median age of 62 years (range 
21–102 years). The descriptive data are presented in Table 1 
and Figure 1.
The annual number of women with incident breast cancer 
nearly doubled in the end of our study period, from a total 
of 962 in 1998 to 1758 in 2009. In 1998–2006, around 58% 
of newly diagnosed breast cancer patients were in the age 
group 50–74 years. However, in 2007–2009, women aged 
50–74 years constituted 70.1% of all newly diagnosed breast 
cancer patients (see Table 2).Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 1 Cumulative survival and crude and adjusted MRRs, and associated 95% confidence intervals, for breast cancer patients 
diagnosed in northern Denmark, 1998–2009
  Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of patients 2996 3210 3126 4424
Median age (years) 62 62 62 63
1 year
Survival, % 90.9 (89.8–91.9) 92.0 (91.0–92.9) 93.2 (92.2–94.0) 94.4 (93.6–95.0)
Mrr 1 (reference) 0.87 (0.73–1.03) 0.74 (0.62–0.89) 0.61 (0.51–0.73)
Mrra 1 (reference) 0.89 (0.75–1.06) 0.74 (0.62–0.89) 0.68 (0.57–0.81)
3 year
Survival, % 78.4 (76.9–79.8) 80.9 (79.5–82.2) 81.6 (80.2–82.9) 83.4 (82.2–84.6)b
Mrr 1 (reference) 0.87 (0.78–0.97) 0.83 (0.74–0.93) 0.73 (0.65–0.81)b
Mrra 1 (reference) 0.89 (0.80–0.99) 0.83 (0.74–0.93) 0.77 (0.68–0.85)b
5 year
Survival, % 70.0 (68.4–71.6) 71.5 (69.9–73.0) 73.0 (71.4–74.5)b 74.7 (73.2–76.1)b
Mrr 1 (reference) 0.93 (0.85–1.02) 0.87 (0.80–0.96)b 0.79 (0.72–0.87)b
Mrra 1 (reference) 0.96 (0.87–1.05) 0.88 (0.80–0.96)b 0.82 (0.75–0.90)b
Notes: aAdjusted for age; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.
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Figure 1 Survival curves for women with breast cancer, according to year of diagnosis, northern Denmark, 1998–2009.
The 1-year overall survival improved gradually from 
90.9% in 1998–2000 to 94.4% in 2007–2009 (Table 1 and 
Figure 1), corresponding to an unadjusted 1-year MRR of 
0.61 (95% CI: 0.51–0.73) in 2007–2009 compared with 
1998–2000. After adjustment for age, the MRR was 0.68 
(95% CI: 0.56–0.79). The 5-year survival was 70.0% in 
1998–2000 and was predicted to be 74.7% in 2007–2009. 
This yielded an adjusted 5-year MRR of 0.79 (95% CI: 
0.72–0.87) (Table 1 and Figure 1).
Among women aged 50–74 years, the 1-year survival 
increased from 92.8% in 1998–2000 to 96.6% in   2007–2009, 
and the 5-year predicted survival increased from 73.9% in 
1998–2000 to 80.2% in 2007–2009 (Table 2). In women aged 
15–49 years and more than 75 years both 1- and 5-year sur-
vival remained virtually unchanged during the study period; in 
the youngest women, the 1-year survivals were 97.0%–97.9%, 
and 5-year survival/predicted survivals were 86.6%–87.6%. In 
the elderly, the 1-year survival was 81.3%–81.1%, and 5-year 
survival was 46.5%–45.9% (Table 2).
Discussion
In this population-based cohort study including nearly 14,000 
breast cancer patients diagnosed between 1998 and 2009, 
we found that survival after breast cancer diagnosis gradu-
ally increased over the entire period. The 1-year mortality 
decreased more than 30%, and the 5-year mortality was Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 2 Survival and associated 95% confidence intervals in women with breast cancer, according to age and year of diagnosis for 
breast cancer patients diagnosed in northern Denmark, 1998–2009
Age (years) Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
15–49
number of patients 567 (18.9%) 636 (19.8%) 598 (19.1%) 615 (13.9%)
1-year survival, % 97.0 (95.2–98.1) 97.3 (95.7–98.3) 98.2 (96.7–99.0) 97.9 (96.3–98.8)
3-year survival, % 90.7 (87.9–92.8) 90.9 (88.4–92.9) 93.0 (90.6–94.8) 93.6 (91.4–95.3)a
5-year survival, % 86.6 (83.5–89.1) 83.9 (80.9–86.6) 87.2 (84.2–89.6)a 87.6 (84.7–90.0)a
50–74
number of patients 1745 (58.2) 1875 (58.4%) 1826 (58.4%) 3102 (70.1%)
1-year survival, % 92.8 (91.5–93.9) 94.5 (93.3–95.4) 95.1 (94.0–96.0) 96.6 (95.9–97.2)
3-year survival, % 81.6 (79.8–83.4) 86.0 (84.3–87.5) 85.0 (83.3–86.5) 87.3 (85.9–88.6)a
5-year survival, % 73.9 (71.8–75.9) 77.5 (75.5–79.3) 78.0 (76.0- 79.8)a 80.2 (78.4–81.9)a
75+
number of patients 684 (22.8%) 699 (21.8%) 702 (22.5%) 707 (16.0%)
1-year survival, % 81.1 (78.0–83.9) 80.7 (77.6–83.4) 83.8 (80.8–86.3) 81.3 (78.2–84.1)
3-year survival, % 59.9 (56.2–63.5) 58.4 (54.6–61.9) 63.1 (59.4–66.5) 60.5 (56.9–64.0)a
5-year survival, % 46.5 (42.7–50.2) 44.2 (40.5–47.8) 47.7 (44.0–51.4)a 45.9 (42.2–49.5)a
Note: aPredicted values.
predicted to decrease by 20%. In the end of our study period, 
however, the annual number of women diagnosed with breast 
cancer nearly doubled.
The main strength of our study is the population-based 
design with a well defined catchment area and virtually com-
plete follow-up, which minimizes the potential for selection 
bias. The use of data from the DNRP allowed for analyses 
updated to recent calendar years; however, the codes from the 
DNRP may not be entirely accurate. A previous Danish study 
conducted in northern Denmark compared ovarian cancer 
diagnoses recorded in the DNRP with similar data from the 
Danish Cancer Registry. The completeness of ovarian cancer 
diagnoses in the DNRP was 96%, and the positive predictive 
value was 87%.20 Thus, we cannot rule out some misclas-
sification of our patients, and if the positive predictive value 
increased over the study period this may have influenced our 
estimates. However, we find it likely that women without a 
breast cancer diagnosis have a better survival than women 
with a breast cancer diagnosis. Therefore, we do expect 
improved predictive values to result in decreased survival. Our 
study has other limitations worth addressing. We do not have 
information on cancer stage, tumor size, hormone receptor 
status, choice of medical treatment, comorbidity, or lifestyle; 
all of which have an impact on breast cancer outcome.12,21 
Mortality trends among younger women with breast cancer 
could likely almost entirely be driven by breast cancer and its 
treatment, while mortality among older women is probably 
influenced by comorbidity. The improved survival among 
50–74-year-old women in our study could thus to some extent 
be explained by improved survival in this age category in the 
general population. We are, however, unable to address the 
impact of these factors on the change we observed in breast 
cancer survival.
The weakness of the hybrid analysis design is that it may 
not be as accurate as directly observed survival. However, 
since we based our predictions on the survival experience in 
the previous period of our study, we expect our predictions 
to be conservative estimates of the increased survival among 
women with breast cancer.
Our finding of an improved breast cancer survival in cen-
tral and northern Denmark extends the findings by Coleman 
et al3 based on data from the Danish Cancer Registry that 
relative 1- and 5-year survival improved during the period 
1995–2007 and Mouridsen et al12 who based their study on 
data from the DBCG and similarly found an increased sur-
vival during the period 1977–2006. Mouridsen et al report an 
overall 5-year survival of 81% in 2002–2006, which is higher 
than the 5-year survival of 73% we found in 2004–2006. The 
DBCG is not entirely complete, as the registration earlier on 
of patients, who were not operated, was very limited, and this   
may explain differences in survival.
Several factors may explain the increase in survival that 
we observed. One possibility is changes in diagnostic pro-
cedures leading to earlier diagnosis. Breast cancer screening 
was introduced in our regions and offered to all women aged 
50–69 years biennially in 2007 and 200816 and may explain 
the nearly two-fold increase in the annual number of breast 
cancers in that period. If this increase in breast cancer inci-
dence mainly occurred in tumors which were less aggressive 
than tumors detected outside screening programs, survival Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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in the latest period may be affected by length time bias.22 
Since the aim of screening is to detect cancers at an earlier 
stage,16 survival will also be prolonged even without change in 
time of death (lead time bias). However, we also observed 
improvement in survival before the screening program was 
implemented. Thus other factors must be involved.
The technical quality of diagnostic imaging with digital 
mammography, high resolution ultrasound, stereotactic biop-
sies, and adjunct MRI mammography has improved over the 
years23–26 so cancers could be detected at an earlier stage, even 
before the introduction of the screening program.
However, the treatment of breast cancer in Denmark dur-
ing our study period has changed towards treatment by spe-
cialized breast surgeons working in multidisciplinary teams 
in centralized units with a higher volume of patients than just 
a few years ago.27 This specialization might have contributed 
to the improved survival.9 More widespread use of standard-
ized treatment following the DBCG protocols may also have 
had an important impact on the improved survival.12 These 
treatment changes include extended indications of adjuvant 
treatment with chemotherapy, endocrine treatment, biologi-
cal treatment, and radiation therapy for smaller tumors, lower 
disease grades, and different age categories.8
In conclusion, survival among breast cancer patients 
has improved in Denmark over the time period 1998–2009, 
and this change was most pronounced in women aged 
50–74 years. Introduction of a screening program in the 
last part of our study period might have contributed to these 
findings, but improvement of survival was also observed in 
the first part of our study period before the screening pro-
gram was implemented. This could thus reflect changes in 
adjuvant treatment.
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